Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E24.98 EPS (ttm)2.90 Insider Own6.22% Shs Outstand17.56M Perf Week-10.93%
Market Cap1.28B Forward P/E12.93 EPS next Y5.60 Insider Trans-0.18% Shs Float16.60M Perf Month-0.88%
Income52.15M PEG1.25 EPS next Q0.89 Inst Own92.39% Short Float4.05% Perf Quarter-0.07%
Sales131.31M P/S9.77 EPS this Y-26.85% Inst Trans-0.32% Short Ratio3.99 Perf Half Y34.40%
Book/sh39.92 P/B1.82 EPS next Y25.78% ROA6.94% Short Interest0.67M Perf Year-6.95%
Cash/sh9.62 P/C7.54 EPS next 5Y20.00% ROE8.29% 52W Range49.24 - 94.57 Perf YTD1.47%
Dividend Est.- P/FCF28.45 EPS past 5Y-13.18% ROI7.38% 52W High-23.37% Beta1.02
Dividend TTM- Quick Ratio12.72 Sales past 5Y-3.89% Gross Margin67.06% 52W Low47.18% ATR (14)2.69
Dividend Ex-DateJul 02, 2010 Current Ratio14.15 EPS Y/Y TTM253.69% Oper. Margin7.48% RSI (14)40.35 Volatility3.88% 3.09%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-40.20% Profit Margin39.72% Recom1.20 Target Price116.80
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q199.40% Payout0.00% Rel Volume0.82 Prev Close72.52
Sales Surprise9.58% EPS Surprise108.87% Sales Q/Q-44.22% EarningsFeb 27 BMO Avg Volume168.28K Price72.47
SMA20-4.61% SMA50-3.67% SMA2008.31% Trades Volume137,196 Change-0.07%
Date Action Analyst Rating Change Price Target Change
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Apr-17-24 09:55AM
Apr-08-24 08:15AM
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM Loading…
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
08:00AM Loading…
Mar-04-24 08:00AM
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
08:20AM Loading…
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
Jun-05-23 11:49AM
Jun-02-23 12:39PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
May-17-23 01:59PM
May-16-23 09:56AM
May-12-23 12:08PM
May-11-23 12:25PM
May-08-23 12:32PM
May-06-23 10:13AM
May-05-23 10:00AM
May-04-23 05:45PM
May-02-23 08:30PM
Apr-28-23 02:04PM
Apr-27-23 09:04AM
Apr-26-23 08:00PM
Apr-24-23 04:01PM
Apr-20-23 09:55AM
Apr-19-23 08:30AM
Apr-18-23 12:56PM
Apr-17-23 01:13PM
Apr-14-23 01:48PM
Apr-13-23 06:28AM
Apr-07-23 06:40PM
Apr-06-23 10:23AM
Apr-04-23 12:02PM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davis Todd CChief Executive OfficerMar 25 '24Option Exercise57.3916,015919,147120,160Mar 27 05:47 PM
Aryeh JasonDirectorMar 05 '24Option Exercise39.352,893113,84074,422Mar 06 05:28 PM
Sabba Stephen LDirectorMar 05 '24Option Exercise0.002,893030,819Mar 07 01:27 PM
Sabba Stephen LDirectorMar 05 '24Sale74.301,893140,65028,926Mar 07 01:27 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Sale88.4614012,38429,755Feb 29 06:50 PM
Davis Todd CCHIEF EXECUTIVE OFFICERSep 22 '23Buy59.384,000237,52973,090Sep 25 04:44 PM
KOZARICH JOHN WDirectorMay 16 '23Sale77.204,444343,08138,488May 18 05:18 PM
Sabba Stephen LDirectorMay 10 '23Option Exercise0.006,408032,192May 12 03:43 PM
Sabba Stephen LDirectorMay 10 '23Sale77.136,408494,22525,784May 12 03:43 PM
KOZARICH JOHN WDirectorMay 08 '23Option Exercise18.826,408120,59948,621May 10 07:15 PM
KOZARICH JOHN WDirectorMay 08 '23Sale76.566,408490,62842,213May 10 07:15 PM